Literature DB >> 15736059

Effects of single, double or triple combinations of octreotide, galanin and serotonin on a human pancreatic cancer cell line.

V Tjomsland1, M El-Salhy.   

Abstract

The human pancreatic cancer cell line (SW 1990) was exposed to 0.2 microg/ml of octreotide, galanin or serotonin as single, double or triple combinations. The tumor cells were checked at 3, 6 and 12 hours. In order to determine the number of viable cancer cells, the MTT-assay was used. Proliferation, apoptosis and the expression of epidermal growth factor were detected with immunohistochemistry using the avidin-biotin complex method. In addition, apoptosis was also detected with (TUNEL) method. The primary antibodies used were proliferating cell nuclear antigen (PCNA), anti-poly (ADP-ribose) polymerase (PARP) and anti-human epidermal growth factor. Single treatment with octreotide or serotonin reduced, the number of viable cells and the proliferation index at all observation times. Galanin increased the number of viable cells and the proliferation index. Whereas double treatments containing octreotide reduced the number of viable cells, those containing galanin increased the number. The effect of single, double or triple treatment on the apoptotic index obtained with both TUNEL method and PARP expression varied depending on the combination and the observation time. Octreotide did not affect the tumor cell expression of EGF. Galanin and serotonin, on the other hand, increased the expression of EGF. Whereas triple combination increased the expression of EGF after 6 h, all the other double combinations decreased this expression. It has been concluded that treatment with a combination of octreotide and serotonin may be useful in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15736059     DOI: 10.14670/HH-20.537

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  4 in total

1.  Colorectal cancer patients exhibit increased levels of galanin in serum and colon tissues.

Authors:  Przemysław Kwiatkowski; Janusz Godlewski; Jacek Kieżun; Bartłomiej Emil Kraziński; Zbigniew Kmieć
Journal:  Oncol Lett       Date:  2016-08-23       Impact factor: 2.967

Review 2.  The Galaninergic System: A Target for Cancer Treatment.

Authors:  Manuel Lisardo Sánchez; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2022-08-01       Impact factor: 6.575

3.  Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.

Authors:  Leanne Stevenson; Wendy L Allen; Richard Turkington; Puthen V Jithesh; Irina Proutski; Gail Stewart; Heinz-Josef Lenz; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Clin Cancer Res       Date:  2012-08-02       Impact factor: 12.531

4.  Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells.

Authors:  Takayuki Uehara; Takeharu Kanazawa; Hiroaki Mizukami; Ryosuke Uchibori; Tomonori Tsukahara; Masashi Urabe; Akihiro Kume; Kiyoshi Misawa; Thomas E Carey; Mikio Suzuki; Keiichi Ichimura; Keiya Ozawa
Journal:  Cancer Sci       Date:  2013-12-01       Impact factor: 6.716

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.